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ABSTRACT
As the patents associated with the biologics are
set to expire in the near future, a new type of
therapy appears on the horizon, and it is quite
similar to the biologics. This commentary
examines the biomedical and market issues
surrounding the advent of biosimilars.
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COMMENTARY
The arsenal of treatments for psoriasis continues
to grow. Originally limited to topical steroids,
phototherapy, and systemic therapies, biologics
have not only revolutionized treatment, but
also provided more efficacious management. As
the patents associated with the biologics are set
to expire in the near future, a new type of
therapy appears on the horizon, and it is quite
similar to the biologics. Herein, we discuss the
biomedical and market issues surrounding
biosimilars; this article is based on previously
conducted studies and does not involve any
new studies of human or animal subjects
performed by any of the authors.
Created under the Biologicals Price
Competition and Innovation Act of 2009,
biosimilars are less costly imitations that show
high similarity to an already FDA-approved
biological product, known as the reference
product. In order to be approved by the FDA, a
biosimilar product must show no clinically
meaningful difference from the reference
product. The biosimilar must have the same
mechanism of action, route of administration,
dosage form, and strength as the reference
production [1]. In addition, a biosimilar can
only be approved for the same indications and
conditions that have been previously approved
for the reference product. To be considered an
interchangeable biological product, the
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biosimilar must produce the same clinical result
as the reference product in any given patient [2].
Once a biosimilar has been FDAapproved, health
care providers and patients will rely upon the
safety and effectiveness of the biosimilar just as
they would for the reference product.
Biosimilars have the potential to reduce
treatment costs compared with those of
reference products. While biologic agents may
be more effective compared to most traditional
systemic therapeutic options, their use is
associated with a much higher cost. With
annual costs ranging between $13,000 and
$30,000 per patient, cost effectiveness is an
important consideration for both the patient
and the physician when choosing to use a
biologic agent [3]. Biosimilars may hold the
promise of being a cheaper substitution for
biologics in the future, but their short-term cost
rivals that of developing biologics.
To enter the market, biosimilars need to
overcome barriers that are much more difficult
than typically seen with small-molecule generic
drugs. Safety, pricing, manufacturing, physician
acceptance, and marketing differentiate the
biosimilar market from the generics market.
Compared to an average of 3 years and $1–4
million between development and approval of a
drug in the generic market, it takes 7–8 years to
develop a biosimilar at a cost of between $100
million and $250 million [4, 5]. Also,
companies may be reluctant to develop
biosimilars because it may be just as hard to
get the biosimilar approved by the FDA as it was
for its reference biologic. To offset the cost and
share the intrinsic risk of biosimilar
development, pharmaceutical alliances
between large, well-established companies are
expected to dominate the market. Companies
experienced in manufacturing, especially
manufacturing biologics, will have a
considerable advantage over new companies
with no such manufacturing experience [4].
For example, well-established companies such
as Amgen and Hospira will likely lead because
they already have the research, development,
and marketing expertise required to produce
biologics, while newer companies face a steep
learning curve, a complicated manufacturing
process, and a risky market.
Additionally, biosimilars consist of relatively
large, complex proteins that are often more
difficult to replicate, unlike generic medicines,
which are chemical, small-molecule drugs that
are equivalent in structure and therapy to the
reference agent [6]. Contrary to chemical
synthesis, the living systems in which
biosimilars are produced are inherently
variable. Biologics are manufactured through
complex engineering that involves genetically
modified unique cell lines designed to produce
the desired antibody and purification processes
that monitor for possible variations. Biosimilars
are produced using different cell lines and
extraction/purification processes than the
reference product [7]. This results in
heterogenicity due to variations in
posttranslational modifications, such as
glycosylation, or physical and chemical
degradation, including deamidation, cleavage,
and aggregation [6]. Therefore, biosimilars are
not identical to the reference product and
consist of a mixture of variants of the same
protein. For this reason, evaluation includes
pharmaco-toxicological, pharmokinetic,
pharmodynamic, efficacy, and clinical safety
studies with emphasis on the immunogenicity
of the biosimilar.
Currently in Europe, two infliximab
biosimilars have reached the market:
Remsima and Inflectra. They are the same
molecule (CT-p13), which is commercialized
under two different names by the
manufacturers Celltrion and Hospira,
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respectively. Both are biosimilars to
infliximab, the 1gG1 chimeric human-murine
monoclonal antibody that targets TNF-a. The
European Medicines Agency (EMA) approved
these biosimilars after reviewing their efficacy
and safety in a phase 1 pharmokinetic study
of patients with ankylosing spondylitis and in
a phase 3 study evaluating efficacy in patients
with rheumatoid arthritis [8, 9]. The EMA
extrapolated from these studies to approve
Remsima and Inflectra for treatment of
psoriasis. More recently, four patients with
severe psoriasis resistant to systemic therapies
underwent treatment with Remsima [10].
Patients were treated with Remsima in a
similar manner as with infliximab: 5 mg/kg
IV at weeks 0, 2, and 6, and then every
8 weeks. After treatment, three of four (3/4)
patients achieved almost complete remission,
while the last achieved a reduction in skin
symptoms. The study concluded that Remsima
was comparable to infliximab in efficacy and
safety, although the power to detect
meaningful differences was limited [10].
Recently, the FDA approved the infliximab
biosimilar Inflectra. Inflectra has been approved
for the treatment of Crohn’s disease, ulcerative
colitis, rheumatoid arthritis, ankylosing
spondylitis, psoriatic arthritis, and plaque
psoriasis. While Inflectra has been approved as
a biologic, it is yet to be determined if it will be
approved to be ‘‘interchangeable.’’ A biologic
approved as interchangeable may be substituted
for the reference product without the
prescriber’s knowledge, and in the US, this can
result in automatic substitution [11]. As such,
determination of interchangeability requires a
higher level of evidence. The biosimilar is
expected to produce the same clinical result as
the reference product in any given patient, and,
if the biosimilar is administered more than once
to an individual, the risk of adverse events or
diminished efficacy of alternating or switching
between the use of the biosimilar and the
reference product is not greater than the risk
of using the reference product alone [1, 2].
However, the FDA has not yet established
criteria that must be met to obtain the status
of interchangeable, and it is unlikely that any
biosimilar will receive that designation anytime
soon [1]. Even if a medication were to be
considered ‘‘interchangeable,’’ legislation for
automatic substitution is up to each state,
regardless of the FDA’s designation [12].
The interest in biosimilars is growing. The
potential for automatic substitutions, the
inherent variability that exists with
biosimilars, and the possibility for
immunogenicity and antibody formation are
concerns that many dermatologists will have as
biosimilars hit the market. While many hope
that the introduction of biosimilars will
improve access to treatment and lessen the
economic burden on healthcare, it remains
important that biosimilars undergo
head-to-head comparison with the reference
product at every step during development to
ensure high similarity, safety, and efficacy. A
biosimilar version of etanercept and
adalimumab could be available in the US
within the next 3 years. Already, clinical trials
are underway to compare the efficacy and
safety of etanercept and adalimumab to their
biosimilar counterparts [13, 14]. Given the
potential for differences in immunogenicity
between the reference product and biosimilar,
the postmarketing surveillance applied to
biologics should also be applied to
biosimilars. Postmarketing programs will
determine efficacy and safety of biosimilars,
while ensuring their similarity to the reference
product.
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